Literature DB >> 16391798

T-cell response to p53 tumor-associated antigen in patients with colorectal carcinoma.

Marco Bueter1, Martin Gasser, Nicolai Schramm, Tatiana Lebedeva, Georges Tocco, Christiane Gerstlauer, Martin Grimm, Ekaterina Nichiporuk, Andreas Thalheimer, Arnulf Thiede, Detlef Meyer, Gilles Benichou, Ana Maria Waaga-Gasser.   

Abstract

Despite the radical surgical resection performed in patients with colorectal carcinoma, there is a high rate of tumor recurrence. Over an observation period of 3 years, 18% of the patients in our collective suffered a tumor relapse with local or distinct metastases after initial R0-resection. Some evidence suggests that this may be due to suppression of anti-tumor responses, a phenomenon that might be attributed to regulatory T cells. The aim of our study was to investigate the tumor-specific immune response depending on the UICC stage of patients with colorectal cancer. The cellular immune responses against defined antigens that are overexpressed in most of the patients with colorectal cancer were characterized. For this purpose, the tumor suppressor gene, p53, was chosen as the tumor-associated antigen that exhibits mutations and overexpression in up to 60% of colorectal carcinoma. We observed that p53 induced both IFN-gamma and IL-10 secretion. The predominance of IL-10 production indicated that regulatory T cells directly participate in modulating the anti-tumor immune response. IL-10 levels in the blood as well as the expression of regulatory T-cell specific genes at the tumor site correlate with the UICC stage of the disease. These results may provide an explanation for the poor prognosis and increased recurrence rate in patients with advanced carcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16391798

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

1.  Evaluation of immunological escape mechanisms in a mouse model of colorectal liver metastases.

Authors:  Martin Grimm; Martin Gasser; Marco Bueter; Johanna Strehl; Johann Wang; Ekaterina Nichiporuk; Detlef Meyer; Christoph T Germer; Ana M Waaga-Gasser; Andreas Thalheimer
Journal:  BMC Cancer       Date:  2010-03-07       Impact factor: 4.430

2.  Tumor necrosis factor-α is associated with positive lymph node status in patients with recurrence of colorectal cancer-indications for anti-TNF-α agents in cancer treatment.

Authors:  M Grimm; M Lazariotou; S Kircher; A Höfelmayr; C T Germer; B H A von Rahden; A M Waaga-Gasser; M Gasser
Journal:  Cell Oncol (Dordr)       Date:  2011-08       Impact factor: 6.730

3.  CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer.

Authors:  Kazuaki Chikamatsu; Koichi Sakakura; Goro Takahashi; Atsushi Okamoto; Nobuhiko Furuya; Theresa L Whiteside; Albert B DeLeo; Keisuke Masuyama
Journal:  Cancer Immunol Immunother       Date:  2009-01-28       Impact factor: 6.968

4.  Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides.

Authors:  Koichi Sakakura; Kazuaki Chikamatsu; Nobuhiko Furuya; Ettore Appella; Theresa L Whiteside; Albert B Deleo
Journal:  Clin Immunol       Date:  2007-07-12       Impact factor: 3.969

5.  Intestinal Regulatory T Cells.

Authors:  Vanessa R Figliuolo da Paz; Deepa R Jamwal; Pawel R Kiela
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 6.  T cells and adoptive immunotherapy: recent developments and future prospects in gastrointestinal oncology.

Authors:  Amedeo Amedei; Elena Niccolai; Mario M D'Elios
Journal:  Clin Dev Immunol       Date:  2011-11-03

7.  Regulatory T cells in colorectal cancer: from biology to prognostic relevance.

Authors:  Dimitrios Mougiakakos
Journal:  Cancers (Basel)       Date:  2011-03-29       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.